Recombinant human thyroid-stimulating hormone is effective for radioiodine ablation of post-surgical thyroid remnants

Nuclear Medicine Communications

Volumn 27, Issue 8, 2006, Pages 627-632

  Barbaro, Daniele ^a   Boni, Giuseppe ^b   Meucci, Giuseppe ^a   Simi, Umberto ^a   Lapi, Paola ^a   Orsini, Paola ^a   Pasquini, Cristina ^a   Turco, Anna ^a   Mariani, Giuliano ^a  

^a Ospedali Riuniti di Livorno   (Italy)

^b UNIVERSITY OF PISA   (Italy)

Author keywords

Differentiated thyroid cancer; Radiometabolic treatment; RhTSH

Indexed keywords

IODINE 131; LEVOTHYROXINE; LIOTHYRONINE; RECOMBINANT THYROTROPIN; THYROGLOBULIN; THYROID HORMONE; THYROXINE;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER PATIENT; CANCER STAGING; COMPARATIVE STUDY; CONTROLLED STUDY; DIET THERAPY; DRUG UPTAKE; FEMALE; FOLLICULAR CARCINOMA; FREE LIOTHYRONINE INDEX; FREE THYROXINE INDEX; HUMAN; MAJOR CLINICAL STUDY; MALE; PAPILLARY CARCINOMA; THYROGLOBULIN BLOOD LEVEL; THYROID HORMONE BLOOD LEVEL; THYROIDECTOMY; WHOLE BODY SCINTISCANNING;

ADULT; AGED; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RECOMBINANT PROTEINS; THYROID NEOPLASMS; THYROTROPIN; TREATMENT OUTCOME;

EID: 33748114927     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/00006231-200608000-00005     Document Type: Article

References (23)

1. Robbins RJ, Tuttle RM, Sharaf RN, Larson SM, Robbins HK, Ghossein RA, et al. Preparations by recombinant human thyrotropin hormone withdrawal are comparable for the detection of residual differentiated thyroid carcinoma. J Clin Endocrinol Metab 2001; 86:619-625.
2. Mazzaferri EL, Kloos RT. Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation? J Clin Endocrinol Metab 2002; 87:1490-1498.
3. Mazzaferri EL, Robbins RJ, Spencer CA, Braverman LE, Pacini F, Wartofsky L, et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 2003; 88:1433-1441.
4. Schlumberger M, Pacini F, Wiersinga WM, Toft A, Smit JV, Sanchez Franco F, et al. Follow up and management of differentiated thyroid carcinoma: a European perspective in clinical practice. Eur J Endocrinol 2004; 151:539-548.
5. Pellegriti G, Scollo C, Giuffrida D, Vigneri R, Squatrito S, Pezzino V. Usefulness of recombinant human thyrotrophin in the radiometabolic treatment of selected patients with thyroid cancer. Thyroid 2001; 11:1025-1030.
6. Chiu AC, Delpassand ES, Sherman SI. Prognosis and treatment of brain metastases in thyroid carcinoma. J Clin Endocrinol Metab 1997; 82:3637-3642.
7. Adler ML, Macapinlac HA, Robbins RJ. Radioiodine treatment of thyroid cancer with the aid of recombinant human thyrotropin. Endocr Pract 1998; 4:282-286.
8. Robbins RJ, Voelker E, Wang W, Macapinlac HA, Larson SM. Compassionate use of recombinant human thyrotropin to facilitate radioiodine therapy: case report and review of literature. Endocr Pract 2000; 6:460-464.
9. Robbins RJ, Tuttle RM, Sonenberg M, Shaha A, Sharaf R, Robbins H, et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin. Thyroid 2001; 11:865-869.
10. Berg G, Lindstedt G, Suurkula M, Jansson S. Radioiodine ablation and therapy in differentiated thyroid cancer under stimulation with recombinant human thyroid-stimulating hormone. J Endocrinol Invest 2002; 25:44-52.
11. Pacini F, Molinaro E, Castagna MG, Lippi F, Ceccarelli C, Agate L, et al. Ablation of thyroid residues with 30 mCi (131)I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal. J Clin Endocrinol Metab 2002; 87:4059-4062.
12. Barbaro D, Boni G, Meucci G, Simi U, Lapi P, Orsini P, et al. Radioiodine treatment with 30 mCi after recombinant human TSH stimulation in thyroid cancer: effectiveness for post-surgical remnants ablation and possible role of iodine content in L-T4 in the outcome of ablation. J Clinical Endocrinol Metab 2003; 88:4110-4114.
13. De Groot LJ, Kaplan EL, McMormick M, Strauss F. Natural history, treatment and course of papillary thyroid carcinoma. J Clin Endocrinol Metab 1990; 71:414-424.
14. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994; 97:418-428.
15. Sclumberger M. Papillary and follicular thyroid carcinoma. N Engl J Med 1998; 338:297-306.
16. Ralli M, Cohan P, Lee K. Successful use of recombinant human thyrotropin in the therapy of pediatric well-differentiated thyroid cancer. J Endocrinol Invest 2005; 28:270-273.
17. Park JT, Hennessey JV. Two-week low iodine diet is necessary for adequate outpatient preparation for radioiodine rhTSH scanning in patients taking levothyroxine. Thyroid 2004; 14:57-63.
18. Loffler M, Weckesser M, Franzius C, Kies P, Schober O. Iodine excretion during stimulation with rhTSH in differentiated thyroid carcinoma. Nuclearmedizin 2003; 42:240-243.
19. Maruca J, Santner S, Miller K, Santen RJ. Prolonged iodine clearance with a depletion regimen for thyroid carcinoma: concise communication. J Nucl Med 1984; 25:1089-1093.
20. Kogai T, Endo T, Saito T, Miyazaki A, Kawaguchi A, Onaya T. Regulation by thyroid-stimulating hormone of sodium/iodidesymporter gene expression and protein levels in FRTL-5 cells. Endocrinology 1997; 138:2227-2232.
21. Duick DS, Baskin HJ. Utility of recombinant human thyrotropin for augmentation of radioiodine uptake and treatment of non-toxic and toxic multinodular goiters. Endocrine Practice 2003; 9:204-209.
22. 131I activities given after recombinant human thyroid-stimulating hormone to treat metastatic differentiated thyroid cancer. J Nucl Med 2004; 45:1549-1554.
23. 131I. J Nucl Med 2003; 44:1069-1071.